Leonteq Securities AG’s Kymera Therapeutics KYMR Stock Holding History

Leonteq Securities AG’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.9K	Buy	+200	New	+$17.2K	﹤0.01%	939
2023 Q2	–	Sell	-2,955	Closed	-$87.6K	–	1273
2023 Q1	$87.6K	Hold	2,955	–	–	﹤0.01%	667
2022 Q4	$73.8K	Buy	+2,955	New	+$78.8K	﹤0.01%	741
2022 Q2	–	Sell	-2,477	Closed	-$105K	–	1315
2022 Q1	$105K	Sell	2,477 -1,415	-36%	-$59.8K	﹤0.01%	727
2021 Q4	$247K	Buy	+3,892	New	+$227K	0.01%	580

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Leonteq Securities AG's KYMR Position: Q2 2026 in Review

Leonteq Securities AG opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 200 shares worth $22.9K. The stake represents ﹤0.01% of the portfolio and ranks #939 among its holdings. This is a return to the name: Leonteq Securities AG previously reported a position in KYMR as recently as Q1 2023.

Leonteq Securities AG first reported a position in KYMR in Q4 2021 and has held it in 5 quarters since. The position peaked at $247K in Q4 2021. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Leonteq Securities AG held 200 shares of Kymera Therapeutics worth $22.9K as of Q2 2026.
Kymera Therapeutics was a new Leonteq Securities AG position in Q2 2026.
Kymera Therapeutics made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #939 holding.
Leonteq Securities AG first reported a position in Kymera Therapeutics in Q4 2021 and has held it in 5 quarters since.
Leonteq Securities AG's Kymera Therapeutics position peaked at $247K in Q4 2021.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.